[1] ORDÁS I, ECKMANN L, TALAMINI M, et al. Ulcerative colitis[J]. Lancet, 2012, 380(9853): 1606-1619. doi:  10.1016/S0140-6736(12)60150-0
[2] MOWAT C, COLE A, WINDSOR A, et al. Guidelines for the management of inflammatory bowel disease in adults[J]. Gut, 2011, 60(5): 571-607. doi:  10.1136/gut.2010.224154
[3] LI Z Y, ZHENG S L, WANG P, et al. Subfatin is a novel adipokine and unlike meteorin in adipose and brain expression[J]. CNS Neurosci Ther, 2014, 20(4): 344-354. doi:  10.1111/cns.12219
[4] ROLAND J, Jørgensen, . Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo[J]. Exp Neurol, 2012, 233(1): 172-181. doi:  10.1016/j.expneurol.2011.09.027
[5] LI Z Y, SONG J, ZHENG S L, et al. Adipocyte metrnl antagonizes insulin resistance through PPARγ signaling[J]. Diabetes, 2015, 64(12): 4011-4022. doi:  10.2337/db15-0274
[6] WATANABE K, AKIMOTO Y, YUGI K, et al. Latent process genes for cell differentiation are common decoders of neurite extension length[J]. J Cell Sci, 2012, 125(Pt 9): 2198-2211.
[7] RAJESH R, Rao, . Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis[J]. Cell, 2014, 157(6): 1279-1291. doi:  10.1016/j.cell.2014.03.065
[8] ZHANG S L, LI Z Y, WANG D S, et al. Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells[J]. Acta Pharmacol Sin, 2020, 41(6): 763-770. doi:  10.1038/s41401-019-0343-4
[9] ZHANG SL, WANG SN, MIAO CY. Influence of microbiota on intestinal immune system in ulcerative colitis and its intervention[J]. Front Immunol, 2017, 8: 1674. doi:  10.3389/fimmu.2017.01674
[10] KEUBLER L M, BUETTNER M, HÄGER C, et al. A multihit model: colitis lessons from the interleukin-10-deficient mouse[J]. Inflamm Bowel Dis, 2015, 21(8): 1967-1975. doi:  10.1097/MIB.0000000000000468
[11] Dan, Turner, . Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report[J]. J Crohn’s Colitis, 2014, 8(11): 1464-1470. doi:  10.1016/j.crohns.2014.05.010
[12] QIN J J, LI R Q, RAES J, et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature, 2010, 464(7285): 59-65. doi:  10.1038/nature08821
[13] LI Z Y, FAN M B, ZHANG S L, et al. Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides[J]. Acta Pharmacol Sin, 2016, 37(11): 1458-1466. doi:  10.1038/aps.2016.70
[14] HU G, LIU J, ZHEN Y Z, et al. Rhein lysinate increases the Median survival time of SAMP10 mice: protective role in the kidney[J]. Acta Pharmacol Sin, 2013, 34(4): 515-521. doi:  10.1038/aps.2012.177
[15] TANG R Q, WEI Y R, LI Y M, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3): 534-541. doi:  10.1136/gutjnl-2016-313332
[16] ZUO L G, GE S T, GE Y Y, et al. The adipokine metrnl ameliorates chronic colitis in il-10-/ - mice by attenuating mesenteric adipose tissue lesions during spontaneous colitis[J]. J Crohns Colitis, 2019, 13(7): 931-941. doi:  10.1093/ecco-jcc/jjz001
[17] HOOPER L V, LITTMAN D R, MACPHERSON A J. Interactions between the microbiota and the immune system[J]. Science, 2012, 336(6086): 1268-1273. doi:  10.1126/science.1223490
[18] AZIZ Q, DORÉ J, EMMANUEL A, et al. Gut microbiota and gastrointestinal health: current concepts and future directions[J]. Neurogastroenterol Motil, 2013, 25(1): 4-15. doi:  10.1111/nmo.12046
[19] SCALDAFERRI F, PIZZOFERRATO M, GERARDI V, et al. The gut barrier: new acquisitions and therapeutic approaches[J]. J Clin Gastroenterol, 2012, 46 Suppl: S12-S17.
[20] SENDER R, FUCHS S, MILO R. Revised estimates for the number of human and bacteria cells in the body[J]. PLoS Biol, 2016, 14(8): e1002533. doi:  10.1371/journal.pbio.1002533
[21] ARUMUGAM M, RAES J, PELLETIER E, et al. Enterotypes of the human gut microbiome[J]. Nature, 2011, 473(7346): 174-180. doi:  10.1038/nature09944
[22] WEXLER H M. Bacteroides: the good, the bad, and the nitty-gritty[J]. Clin Microbiol Rev, 2007, 20(4): 593-621. doi:  10.1128/CMR.00008-07
[23] SARKIS K, Mazmanian, . An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system[J]. Cell, 2005, 122(1): 107-118. doi:  10.1016/j.cell.2005.05.007
[24] CHIU CC, CHING YH, WANG YC, et al. Monocolonization of germ-free mice with Bacteroides fragilis protects against dextran sulfate sodium-induced acute colitis[J]. Biomed Res Int, 2014, 675786.
[25] KUWAHARA T, YAMASHITA A, HIRAKAWA H, et al. Genomic analysis of Bacteroides fragilis reveals extensive DNA inversions regulating cell surface adaptation[J]. Proc Natl Acad Sci USA, 2004, 101(41): 14919-14924. doi:  10.1073/pnas.0404172101
[26] ALAMEDDINE J, GODEFROY E, PAPARGYRIS L, et al. Faecalibacterium prausnitzii skews human DC to prime IL10-Producing T cellsthrough TLR2/6/JNK signaling and IL-10, IL-27, CD39, and IDO-1 induction[J]. Front Immunol, 2019, 10: 143. doi:  10.3389/fimmu.2019.00143
[27] PATTERSON AM, MULDER IE, TRAVIS AJ, et al. Human gut symbiont roseburia hominis promotes and regulates innate immunity[J]. Front Immunol, 2017, 8: 1166. doi:  10.3389/fimmu.2017.01166
[28] MUKHERJEE A, LORDAN C, ROSS RP, et al. Gut microbes from the phylogenetically diverse genus eubacterium and their various contributions to gut health[J]. Gut Microbes, 2020, 12(1): 1802866. doi:  10.1080/19490976.2020.1802866
[29] IMAOKA A, SHIMA T, KATO K, et al. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells[J]. World J Gastroenterol, 2008, 14(16): 2511-2516. doi:  10.3748/wjg.14.2511
[30] ARBOLEYA S, WATKINS C, STANTON C, et al. Gut bifidobacteria populations in human health and aging[J]. Front Microbiol, 2016, 7: 1204.
[31] BEN P, Willing, . A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes[J]. Gastroenterology, 2010, 139(6): 1844-1854. e1. doi:  10.1053/j.gastro.2010.08.049
[32] TAKAHASHI K, NISHIDA A, FUJIMOTO T, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in crohn’s disease[J]. Digestion, 2016, 93(1): 59-65. doi:  10.1159/000441768
[33] MOUSTAFA A, LI W, ANDERSON EL, et al. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease[J]. Clin Transl Gastroenterol, 2018, 9(1): e132. doi:  10.1038/ctg.2017.58
[34] KLEESSEN B, KROESEN A J, BUHR H J, et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls[J]. Scand J Gastroenterol, 2002, 37(9): 1034-1041. doi:  10.1080/003655202320378220
[35] GOPHNA U, SOMMERFELD K, GOPHNA S, et al. Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis[J]. J Clin Microbiol, 2006, 44(11): 4136-4141. doi:  10.1128/JCM.01004-06
[36] KANG S, DENMAN S E, MORRISON M, et al. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray[J]. Inflamm Bowel Dis, 2010, 16(12): 2034-2042. doi:  10.1002/ibd.21319
[37] MARTINEZ-MEDINA M, GARCIA-GIL L J. Escherichia coli in chronic inflammatory bowel diseases: an update on adherent invasive Escherichia coli pathogenicity[J]. World J Gastrointest Pathophysiol, 2014, 5(3): 213-227. doi:  10.4291/wjgp.v5.i3.213
[38] CHERVY M, BARNICH N, DENIZOT J. Adherent-invasive E. coli: update on the lifestyle of a troublemaker in crohn’s disease[J]. Int J Mol Sci, 2020, 21(10): 3734. doi:  10.3390/ijms21103734
[39] THURSBY E, JUGE N. Introduction to the human gut microbiota[J]. Biochem J, 2017, 474(11): 1823-1836. doi:  10.1042/BCJ20160510